Coherus Oncology Inc (CHRS) 13F Holdings Overview (Q2 2026)

CHRS ranks #3709 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

149 institutions disclose a position in CHRS, but none treat it as a major bet — even Timothy G. Youngquist 2020 Irrevocable Trust, its most concentrated holder, allocates just 3.6% of its own portfolio to it.

Timothy G. Youngquist 2020 Irrevocable Trust has trimmed its CHRS position for two straight quarters, cutting it by $5.0M while still holding $15.8M.

CHRS is down 7.5% today, but institutions show net buying of $6.2M this quarter — a divergence between today's price move and the underlying institutional flow.

CHRS reported a net loss of $132.1M over the trailing twelve months.

• Not yet profitable — net loss of $132.1M over the trailing twelve months
• Net income declined year over year, from $179.8M to -$132.1M
• Operating cash flow was negative, using $138.5M in cash
• Current ratio of 1.47x — below the conventional 1.5x liquidity buffer
• Liabilities run 3.23x equity — a highly leveraged balance sheet worth noting